Posts with tag: science
US stocks edge lower on tariff concerns and await Powell's testimony on inflation. Investors assess impact of Trump's tariffs, with gold hitting record highs amidst uncertainty.
Published on: February 11, 2025, 03:04 PM UTC
Uncertainty in Trump’s second term clouds Wall Street’s expectations; Dealmaking slows, tax breaks for hedge funds threatened, big banks grilled on customer banking practices.
Published on: February 11, 2025, 03:02 PM UTC
Automotive retailer Lithia Motors (NYSE:LAD) is reporting earnings tomorrow before market hours. Analysts expect revenue to grow 17.6% year over year to $9.03 billion and adjusted earnings to come in at $7.20 per share.
Published on: February 11, 2025, 02:10 PM UTC
Kraft Heinz Earnings: Analysts expect revenue decline of 2.9% to $6.66B, adjusted earnings of $0.78 per share. Read our analysis for industry trends and stock performance.
Published on: February 11, 2025, 02:08 PM UTC
HubSpot (HUBS) is set to report Q4 earnings tomorrow after the bell. Analysts expect revenue to grow 15.7% YoY to $673.5 million, with adjusted earnings at $2.20 per share. Read our analysis for what to expect.
Published on: February 11, 2025, 02:08 PM UTC
President Trump’s focus on reciprocal tariffs may upend the US trading relationships around the globe. Some American allies could be hit hard due to their high average tariffs. However, other nations with lower average duties than the US argue that any US tariffs applied to them should actually fall.
Published on: February 11, 2025, 02:02 PM UTC
Big Tech's massive AI spending spree in 2023 could be a key indicator for the stock market's direction, according to experts. Tech giants like Microsoft, Alphabet, Amazon, and Meta are set to invest a combined $325 billion in AI, a move that could have significant implications for the market as a whole.
Published on: February 11, 2025, 02:01 PM UTC
Israel Returns to Global Bond Market After War Impact
Published on: February 11, 2025, 01:07 PM UTC
Stocks struggle as tariff news and Fed testimony loom
Published on: February 11, 2025, 01:05 PM UTC
Royalty Pharma (RPRX) missed Q4 revenue estimates but exceeded EPS expectations. Portfolio Receipts beat estimates, and full-year 2025 guidance was above consensus. Despite a decline in operating margin, the company remains highly profitable. Analysts forecast 17.3% revenue growth over the next 12 months. Read our full research report to assess the company's fundamentals and valuation.
Published on: February 11, 2025, 01:04 PM UTC